journal article·2025-05

A CXCR4-targeted immunomodulatory nanomedicine for photodynamic amplified immune checkpoint blockade therapy against breast cancer

Yibin Liu, Xiayun Chen, Wei Zhang, Baixue Yu, Yi Cen, Qianqian Liu, Youzhi Tang, Shiying Li

Acta Biomaterialia· Volume 197
Publisher page

Abstract

The therapeutic efficacy of immune checkpoint blockade (ICB) is critically compromised by inadequate T lymphocyte infiltration, low T cell-induced pro-inflammatory responses, and the accumulation of immunosuppressive cells within the tumor microenvironment (TME). In this work, a chimeric peptide-engineered immunomodulatory nanomedicine (designated as CXNP-CeBM) is developed for photodynamic amplified ICB therapy against breast cancer. CXNP-CeBM is composed of a CXCR4-targeting peptide ((C16)2-KLGASWHRPDK) loaded with the photosensitizer of Ce6 and the PD-1/PD-L1 inhibitor of BMS8. CXNP-CeBM specifically recognizes CXCR4 on breast cancer, thus suppressing CXCR4-mediated signaling pathways and enhancing the intracellular delivery of therapeutic agents. The photodynamic therapy (PDT) of CXNP-CeBM damages primary tumor cells to initiate immunogenic cell death (ICD), leading to the release of high mobility group box 1 (HMGB1) and the exposure of calreticulin (CRT). Simultaneously, the interruption of CXCR4 signaling reduces tumor fibrosis, promotes T-cell infiltration, and decreases the number of immunosuppressive cells, thereby enhancing the immunotherapeutic effect of ICB. Treatment with CXNP-CeBM would activate systemic anti-tumor immunity, leading to effective inhibition of both primary and lung metastatic tumors, while maintaining low systemic toxicity. This work provides a reliable strategy for the delivery of multi-synergistic agents, effectively activating breast cancer immunity through a multifaceted mechanism. STATEMENT OF SIGNIFICANCE: Although immune checkpoint blockade (ICB) has shown great potential for malignant tumor therapy, its efficacy is compromised by immunosuppressive microenvironments. Herein, a CXCR4-targeted immunomodulatory nanomedicine (CXNP-CeBM) was constructed for photodynamic amplified ICB therapy of breast cancer. CXNP-CeBM could selectively deliver photosensitizers and PD-1/PD-L1 inhibitors to breast cancer cells that overexpressed the chemokine receptor CXCR4, while interrupting CXCR4 signaling to reduce tumor fibrosis, promote T-cell infiltration, and decrease the number of immunosuppressive cells. Moreover, CXNP-CeBM induced photodynamic therapy to trigger immunogenic cell death while downregulating the PD-L1 level to destroy immune evasion mechanisms, thus activating immunological cascades to treat both primary and lung metastatic tumors. This study provided a multi-synergistic strategy for breast cancer immunotherapy through a multifaceted mechanism.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (58)

Show source-provided references
1. Canscreen 5, a global repository for breast, cervical and colorectal cancer screening programs10.1038/s41591-023-02315-6 ↗
2. Breast cancer: an up-to-date review and future perspectives10.1002/cac2.12358 ↗
3. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries
4. The cutting-edge progress of immune-checkpoint blockade in lung cancer10.1038/s41423-020-00577-5 ↗
5. The interaction of CD4 (+) helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response
6. Boosting checkpoint immunotherapy with biomaterials10.1021/acsnano.2c11691 ↗
7. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy10.1016/j.apsb.2022.11.001 ↗
8. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response10.1038/s41392-022-01136-2 ↗
9. The future of immune checkpoint therapy10.1126/science.aaa8172 ↗
10. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions10.1038/s41392-023-01332-8 ↗
11. CD8+ T cell differentiation and dysfunction in cancer10.1038/s41577-021-00574-3 ↗
12. Immunogenic cell stress and death10.1038/s41590-022-01132-2 ↗
13. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency
14. Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death10.1016/j.cclet.2021.10.074 ↗
15. Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy10.1038/s41551-018-0203-4 ↗
16. Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy10.1038/s41467-018-04703-w ↗
17. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death
18. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy10.1038/ncomms12499 ↗
19. Targeting immunogenic cell stress and death for cancer therapy
20. How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?10.7150/thno.72465 ↗
21. Engineered metal and their complexes for nanomedicine-elicited cancer immunotherapy10.1016/j.mtadv.2022.100276 ↗
22. Electromagnetic nanomedicines for combinational cancer immunotherapy10.1002/anie.202008386 ↗
23. A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence10.1126/sciadv.abq8225 ↗
24. How chemokines organize the tumour microenvironment10.1038/s41568-023-00635-w ↗
25. The dynamic roles of the bladder tumour microenvironment10.1038/s41585-022-00608-y ↗
26. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling10.1186/s12964-018-0233-2 ↗
27. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets10.1186/s13045-022-01282-8 ↗
28. CXCL12/CXCR4 axis in the microenvironment of solid tumors: a critical mediator of metastasis10.1016/j.lfs.2020.117534 ↗
29. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy10.1016/j.imlet.2019.11.007 ↗
30. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts10.1016/j.addr.2021.02.012 ↗
31. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma10.1038/s41419-022-05351-1 ↗
32. Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy10.1016/j.apsb.2020.08.010 ↗
33. Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer10.1073/pnas.1710754114 ↗
34. Cancer nanotechnology: a new revolution for cancer diagnosis and therapy10.2174/1389200219666180918111528 ↗
35. OGA activated glycopeptide-based nano-activator to activate PKM2 tetramerization for switching catabolic pathways and sensitizing chemotherapy resistance10.1016/j.biomaterials.2022.121523 ↗
36. Aggregation-induced emission: recent advances in materials and biomedical applications10.1002/anie.202000845 ↗
37. Carrier-free nanodrug for the chemical-photodynamic synergistic treatment of lung cancer10.1021/acsanm.4c00659 ↗
38. Highly effective generation of singlet oxygen by an imidazole-linked robust photosensitizing covalent organic framework10.1021/acsnano.2c10423 ↗
39. Cell membrane as a promising therapeutic target: from materials design to biomedical applications
40. A novel chimeric oncolytic virus mediates a multifaceted cellular immune response in a syngeneic B16 melanoma model
41. Nanoplatform-based strategies for enhancing the lethality of current antitumor PDT10.1039/D4TB00008K ↗
42. Review of dendritic cells, their role in clinical immunology, and distribution in various animal species10.3390/ijms22158044 ↗
43. Dendritic cells and CD8 T cell immunity in tumor microenvironment10.3389/fimmu.2018.03059 ↗
44. The role of photodynamic therapy in triggering cell death and facilitating antitumor immunology10.3389/fonc.2022.863107 ↗
45. Immunogenic cell death in hematological malignancy therapy
46. Engineering nanomedicines for immunogenic eradication of cancer cells: recent trends and synergistic approaches10.1016/j.apsb.2024.03.022 ↗
47. Endoplasmic reticulum stress and the unfolded protein response: emerging regulators in progression of traumatic brain injury10.1038/s41419-024-06515-x ↗
48. Which cell death modality wins the contest for photodynamic therapy of cancer?10.1038/s41419-022-04851-4 ↗
49. Regulatory mechanisms of PD-1/PD-L1 in cancers10.1186/s12943-024-02023-w ↗
50. Reducing PD-L1 expression by degraders and downregulators as a novel strategy to target the PD-1/PD-L1 pathway10.1021/acs.jmedchem.3c02143 ↗
51. Metformin liposome-mediated PD-L1 downregulation for amplifying the photodynamic immunotherapy efficacy10.1021/acsami.0c21743 ↗
52. Tissue density in the progression of breast cancer: bedside to bench and back again
53. Mechanisms of fibrosis: therapeutic translation for fibrotic disease10.1038/nm.2807 ↗
54. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer10.1073/pnas.1815515116 ↗
55. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy10.1016/j.imlet.2019.11.007 ↗
56. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks10.1038/onc.2015.139 ↗
57. Extramedullary hematopoiesis of the liver and spleen10.3390/jcm10245831 ↗
58. Melanin-based immunoregulatory nanohybrids enhance antitumor immune responses in breast cancer mouse model10.1021/acsnano.3c02287 ↗